(Reuters) -Chinese biotech Hansoh Pharma said on Friday its units have signed a license agreement worth up to $1.45 billion with Roche's subsidiary for an investigational treatment of colorectal
Hansoh Pharma Enters $1.45 Billion Licensing Deal with Roche for Cancer Drug
Overview of the Licensing Agreement
(Reuters) -Chinese biotech Hansoh Pharma said on Friday its units have signed a license agreement worth up to $1.45 billion with Roche's subsidiary for an investigational treatment of colorectal cancer and other solid tumors.
Details of the Agreement
(Reporting by Sneha Kumar in Bengaluru; Editing by Shailesh Kuber)






